News | January 22, 2015

Cleveland HeartLab Acquires MIRISK Heart Attack Risk Assessment Tool

Technology expands its product portfolio and cardiovascular disease assessment capabilities

Cleveland HeartLab, MIRISK, heart attack, risk assessment, blood testing

January 22, 2015 — Cleveland HeartLab (CHL) announced that it has acquired the MIRISK cardiovascular disease (CVD) risk assessment tool. Developed at Stanford University School of Medicine and validated in an eight-year, 5,000-patient clinical study, MIRISK is a highly accurate tool for determining a patient's potential long-term risk of a heart attack. The assessment relies on a proprietary algorithm to analyze key blood proteins associated with the development of vulnerable plaque. Taken together with other known risk factors, MIRISK can determine an individual's probability of experiencing a heart attack within a five-year timeframe. The acquisition by CHL includes intellectual property, copyrights and brand assets of MIRISK, which were previously owned by Aviir.

According to the Centers for Disease Control and Prevention, 600,000 Americans die annually from CVD, more than from all forms of cancer combined. The total cost of CVD in the United States exceeds $400 billion. CVD remains mostly preventable, however, standard risk assessment strategies only identify approximately 50 percent of people who suffer a heart attack. More advanced risk assessment tools can be used to better identify risk, reducing overall cardiovascular events.

"We're incredibly pleased with the acquisition of this technology because it provides Cleveland HeartLab with the most advanced and comprehensive near-term and long-term CVD strategies available today," said Marc Penn, M.D., Ph.D., FACC, director of research at Summa Cardiovascular Institute, and chief medical officer of CHL. "Our proprietary CVD inflammation testing has been validated to show risk assessment in hundreds of studies. MIRISK complements our arsenal of prognostic testing. Together, these two represent a significant leap forward in the advancement of CVD risk assessment and, ultimately, heart attack and stroke prevention."

Vulnerable plaque is a key risk factor in heart attack and plays a pivotal role in over 75 percent of all heart attacks. MIRISK provides both the patient and the physician the knowledge necessary to head off potentially life-threatening cardiac events through both medical interventions and lifestyle changes. The Stanford team that pioneered MIRISK, led by Tom Quertermous M.D., director of research, division of cardiovascular medicine at Stanford University, identified a key group of proteins associated with the development of vulnerable arterial plaque. In a large eight-year study, Quertermous and team demonstrated that these proteins could be measured, analyzed and used to assess the risk of plaque rupture and heart attack as early as five years prior to the event. 

For more information:

Related Content

NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
PURE study may cause revision of fat intake guidelines for cardiology.
Feature | ESC| September 07, 2017
September 7, 2017 — Researchers at the European Society of Cardiology (ESC) Congress called for a reconsideration of
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Advances in FFR, FFR-CT, was the most popular cardiology story in August 2017.

The most popular article in August was about advances in fractional flow reserve (FFR) technologies. The image shows Philips' new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions.

Feature | September 01, 2017 | Dave Fornell
September 1, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Car
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Overlay Init